1. Israel Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
BrainsWay Ltd.

BrainsWay Ltd.

BWAY.TA
BrainsWay Ltd.IL flagTel Aviv Stock Exchange
4,709.00
ILA
-51.00
- -
1.89BMarket Cap
BrainsWay Ltd.
BWAY.TA
(Tel Aviv Stock Exchange)

Recent

price

4,709.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.09
0.24
0.47
0.79
0.75
0.99
1.13
0.98
0.96
0.81
0.98
1.26
1.37
1.46
Revenue per Share
-0.55
-0.46
-0.28
-0.17
-0.48
-0.39
-0.5
-0.24
-0.21
-0.4
-0.13
0.09
0.2
0.23
Basic EPS, GAAP
-0.5
-0.37
-0.47
-0.19
-0.3
-0.35
-0.51
-0.17
-0.04
-0.29
0.04
0.2
0.43
0.3
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-2.92
-3.15
-3.3
-3.72
-3.69
-3.5
-3.43
-2.71
-2.9
-3.13
-3.02
-2.37
-2.28
Book Value per Share
- -
1.1
0.89
0.71
0.86
0.42
1.18
0.88
1.86
1.36
1.29
1.92
1.92
1.96
Tangible Book Value per Share
13
14
14
15
15
17
21
22
31
33
32
32
38
39
Basic Weighted Avg Shares
1
3
7
12
11
16
23
22
30
27
32
41
52
56
Sales/Revenue/Turnover
-358.87
-215.3
-66.25
-17.95
-59.32
-31.19
-36.69
-21.89
-16.86
-46.67
-15.6
3.39
8.28
10.23
Operating Margin (%)
- -
- -
1
1
1
1
2
2
2
2
1
2
2
2
Depreciation Expense
-7
-7
-4
-2
-7
-6
-10
-5
-6
-13
-4
3
8
9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15.55
1
0.45
Effective Tax Rate (%)
-598.99
-193.64
-60.1
-20.8
-63.29
-39.51
-44.71
-24.41
-21.79
-49.12
-13.2
7.12
14.62
15.68
Profit Margin (%)
- -
14
10
9
12
5
22
17
56
50
46
64
63
55
Working Capital
- -
- -
- -
- -
3
2
- -
- -
- -
- -
- -
5
6
6
LT Debt
- -
16
13
10
13
7
24
20
57
45
42
62
73
76
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.16
5.82
7.54
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-4.36
-11.17
-12.64
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
6
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
39
40
Market Capitalization
29,627
37,574
52,589

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
83
85
79
Cash, Cash Equivalents & STI
72
69
60
Accounts Receivable, Net
5
4
8
Inventories
4
7
7
Total Current Liabilities
26
22
24
Payables & Accruals
9
9
11
ST Debt
1
1
1
Deferred Revenue
16
12
12

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
41.77%
46.02%
17.51%
Free Cash Flow
104.85%
199.81%
150.2%
Net Income, GAAP
20.61%
9.95%
161.31%
Sales/Revenue/Turnover
24.91%
19.89%
27.33%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9
10
11
11
41
2025
12
13
14
15
52
2026
16
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
0.02
0.04
0.09
2025
0.03
0.05
0.04
0.08
0.2
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
EOFLOW Co.,Ltd. (294090.KQ)
i-SENS Inc (099190.KS)
Accelerate Diagnostics, Inc. (AXDX)
Euroapi S.A. (EAPI.PA)
RxSight, Inc. (RXST)
CVR Medical Corp. (CRRVF)
Business
BrainsWay Ltd. (NASDAQ & TASE: BWAY.TA), founded in 2003 and headquartered in Jerusalem, Israel, with principal U.S. operations in Burlington, Massachusetts, develops and markets noninvasive neurostimulation treatments utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology for mental health disorders. The company offers FDA-cleared Deep TMS systems for major depressive disorder including anxious depression and late-life depression in patients aged 15 to 86, obsessive-compulsive disorder as the first de novo noninvasive device, and short-term smoking addiction cessation as the inaugural TMS clearance in the addiction category; it targets treatment-resistant patients and operates through over 800 providers in the United States, East Asia, and internationally. BrainsWay pursues ongoing clinical trials in additional psychiatric, neurological, and addiction indications while maintaining dual listings on NASDAQ and the Tel Aviv Stock Exchange. In August 2025, the company acquired a minority stake in Axis Integrated Mental Health for up to $3.3 million through strategic equity financing to support provider growth and Deep TMS adoption, following a prior $5 million convertible loan to Neurolief Ltd. for potential acquisition of complementary neuromodulation technology; these moves align with a late-2024 initiative for minority investments in U.S. mental health providers amid 26% year-over-year Q2 2025 revenue growth to $12.6 million.